Revolutionary Treatment Could Eliminate Cancer and Reduce Invasive Surgeries
A groundbreaking vaccine for bowel cancer is set to be trialled on the NHS and in Australia, offering hope for patients around the world. The vaccine, which will be trialled at the Royal Surrey NHS Foundation Trust, has the potential to completely eradicate the disease by stimulating the body's immune system to attack tumours. This could lead to fewer invasive surgeries and a life-changing treatment option for patients.
World First Treatment Vaccine in Gastrointestinal Cancer
According to Dr. Tony Dhillon, a leading expert at Royal Surrey, this vaccine is a game-changer in the fight against cancer. It is the first treatment vaccine for any gastrointestinal cancer and there are high hopes for its success. Dr. Dhillon believes that for many patients, the cancer may disappear completely after receiving this groundbreaking treatment.
Significance for Bowel Cancer Patients in the UK
Bowel cancer is the UK's second deadliest cancer, with 43,000 people being diagnosed each year and 268,000 currently living with the disease. However, the chances of survival are significantly higher if the cancer is detected at an early stage. The vaccine trial offers hope for improved survival rates and earlier detection of the disease, thanks to the No Time 2 Lose campaign led by Dame Deborah James.
Trials and Potential Impact
The vaccine, developed by immuno-oncology company Imugene Ltd, will be rolled out at 10 sites, with six in Australia and four in the UK. The trial will involve enrolling 44 patients over an 18-month period. If successful, the vaccine will either be licensed for use or further studies will be conducted. The vaccine is administered in three doses, two weeks apart, and patients will undergo an endoscopy and tissue sample to determine eligibility.
Pioneering Collaboration and Future Prospects
Dr. Dhillon, who proposed the trial, has been working with Professor Tim Price in Australia for the past four years to develop this innovative vaccine. The success of this trial could revolutionize the treatment of bowel cancer and provide new hope for patients worldwide. Royal Surrey's Chief Executive, Louise Stead, expressed pride in their involvement and praised the trial's potential to provide real hope for bowel cancer patients.
Did you miss our previous article...
https://trendinginthenews.com/cancer/alarming-rise-in-childhood-obesity-rates-during-the-pandemic
